Boothbay Fund Management LLC Grows Position in Evolus, Inc. (NASDAQ:EOLS)

Boothbay Fund Management LLC lifted its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 30.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,287,767 shares of the company's stock after acquiring an additional 304,065 shares during the quarter. Boothbay Fund Management LLC owned 2.03% of Evolus worth $14,217,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of EOLS. Gilder Gagnon Howe & Co. LLC lifted its position in shares of Evolus by 287.2% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company's stock valued at $7,753,000 after buying an additional 520,859 shares in the last quarter. Oberweis Asset Management Inc. raised its position in Evolus by 31.6% during the fourth quarter. Oberweis Asset Management Inc. now owns 677,600 shares of the company's stock worth $7,481,000 after acquiring an additional 162,700 shares during the period. Price T Rowe Associates Inc. MD raised its position in Evolus by 13.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 52,593 shares of the company's stock worth $581,000 after acquiring an additional 6,332 shares during the period. Diadema Partners LP purchased a new position in Evolus during the fourth quarter valued at $1,076,000. Finally, Stifel Financial Corp grew its position in shares of Evolus by 37.3% in the fourth quarter. Stifel Financial Corp now owns 197,697 shares of the company's stock valued at $2,183,000 after purchasing an additional 53,673 shares during the period. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Stock Down 2.9 %

Shares of EOLS stock traded down $0.34 on Monday, reaching $11.31. 769,437 shares of the stock were exchanged, compared to its average volume of 667,902. The company has a market capitalization of $719.17 million, a price-to-earnings ratio of -12.43 and a beta of 0.97. The business's 50 day moving average price is $12.18 and its 200 day moving average price is $12.86. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a twelve month low of $8.67 and a twelve month high of $17.82.

Analysts Set New Price Targets

A number of research analysts have weighed in on EOLS shares. HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. Barclays increased their target price on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, April 9th. Finally, BTIG Research began coverage on shares of Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $23.75.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $12.40, for a total value of $77,512.40. Following the sale, the insider now owns 508,619 shares of the company's stock, valued at $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Karah Herdman Parschauer sold 12,888 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the sale, the director now owns 32,183 shares of the company's stock, valued at approximately $418,057.17. The trade was a 28.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 60,575 shares of company stock valued at $794,369 over the last three months. 6.10% of the stock is owned by corporate insiders.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.